Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

Follicular Dendritic Cell Sarcoma Presenting As a Thyroid Mass
Starr, Jason S. , Attia, Steven , Joseph, Richard W. , Menke, David M. , Casler, John D., Smallridge, Robert C., Menke, David, Casler, John

Journal of Clinical Oncology | March 25, 2014 | Volume: 33 | Issue: 17 | Pages: e74-e76

10.1200/jco.2013.49.3213 | PMID 24663046 Get It

Airway Uric Acid Is a Sensor of Inhaled Protease Allergens and Initiates Type 2 Immune Responses in Respiratory Mucosa
Hara, Kenichiro , Iijima, Koji, Elias, Martha K., Seno, Satoshi, Kephart, Gail M., Kurabayashi, Masahiko , Kita, Hirohito , Tojima, Ichiro , Kobayashi, Takao , Kita, H

The Journal of Immunology | March 25, 2014 | Volume: 192 | Issue: 9 | Pages: 4032-4042

10.4049/jimmunol.1400110 | PMID 24663677 Get It

Abstract Although type 2 immune responses to environmental Ags are thought to play pivotal roles in asthma and allergic airway diseases, the immunological mechanisms that initiate the responses are largely unknown. Many allergens have biologic activities, including enzymatic activities and abilities to engage innate pattern-recognition receptors such as TLR4. In this article, we report that IL-33 and thymic stromal lymphopoietin were produced quickly in the lungs of naive mice exposed to cysteine proteases, such as bromelain and papain, as a model for allergens. IL-33 and thymic stromal lymphopoietin sensitized naive animals to an innocuous airway Ag OVA, which resulted in production of type 2 cytokines and IgE Ab, and eosinophilic airway inflammation when mice were challenged with the same Ag. Importantly, upon exposure to proteases, uric acid (UA) was rapidly released into the airway lumen, and removal of this endogenous UA by uricase prevented type 2 immune responses. UA promoted secretion of IL-33 by airway epithelial cells in vitro, and administration of UA into the airways of naive animals induced extracellular release of IL-33, followed by both innate and adaptive type 2 immune responses in vivo. Finally, a potent UA synthesis inhibitor, febuxostat, mitigated asthma phenotypes that were caused by repeated exposure to natural airborne allergens. These findings provide mechanistic insights into the development of type 2 immunity to airborne allergens and recognize airway UA as a key player that regulates the process in respiratory mucosa.
Physiological underpinnings of irritable bowel syndrome: neurohormonal mechanisms
Camilleri, Michael

The Journal of Physiology | March 25, 2014 | Volume: 592 | Issue: 14 | Pages: 2967-2980

10.1113/jphysiol.2014.270892 | PMID 24665101 Get It

AbstractThe gastrointestinal tract is a vast neuroendocrine organ with extensive extrinsic and intrinsic neural circuits that interact to control its function. Circulating and paracrine hormones (amine and peptide) provide further control of secretory, absorptive, barrier, motor and sensory mechanisms that are essential to the digestion and assimilation of nutrients, and the transport and excretion of waste products. Specialized elements of the mucosa (including enteroendocrine cells, enterocytes and immune cells) and the microbiome interact with other intraluminal contents derived from the diet, and with endogenous chemicals that alter the gut's functions. The totality of these control mechanisms is often summarized as the brain–gut axis. In irritable bowel syndrome (IBS), which is the most common gastrointestinal disorder, there may be disturbances at one or more of these diverse control mechanisms. Patients present with abdominal pain in association with altered bowel function. This review documents advances in understanding the pathophysiological mechanisms in the brain–gut axis in patients with IBS. It is anticipated that identification of one or more disordered functions in clinical practice will usher in a renaissance in the management of IBS, leading to effective therapy tailored to the needs of the individual patient.
Financial Management of a Large Multisite Randomized Clinical Trial
Sheffet, Alice J., Flaxman, Linda, Tom, MeeLee , Hughes, Susan , Longbottom, Mary, Howard, Virginia J. , Marler, John R., Brott, Thomas G. , Investigators, for the CREST, Investigators, for the CREST, Howard, Virginia J

International Journal of Stroke | March 25, 2014 | Volume: 9 | Issue: 6 | Pages: 811-813

10.1111/ijs.12259 | PMID 24661748 Get It

Background The Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) received five years' funding ($21 112 866) from the National Institutes of Health to compare carotid stenting to surgery for stroke prevention in 2500 randomized participants at 40 sites. Aims Herein we evaluate the change in the CREST budget from a fixed to variable-cost model and recommend strategies for the financial management of large-scale clinical trials. Methods Projections of the original grant's fixed-cost model were compared to the actual costs of the revised variable-cost model. The original grant's fixed-cost budget included salaries, fringe benefits, and other direct and indirect costs. For the variable-cost model, the costs were actual payments to the clinical sites and core centers based upon actual trial enrollment. We compared annual direct and indirect costs and per-patient cost for both the fixed and variable models. Differences between clinical site and core center expenditures were also calculated. Results Using a variable-cost budget for clinical sites, funding was extended by no-cost extension from five to eight years. Randomizing sites tripled from 34 to 109. Of the 2500 targeted sample size, 138 (5·5%) were randomized during the first five years and 1387(55·5%) during the no-cost extension. The actual per-patient costs of the variable model were 9% ($13 845) of the projected per-patient costs ($152 992) of the fixed model. Conclusions Performance-based budgets conserve funding, promote compliance, and allow for additional sites at modest additional cost. Costs of large-scale clinical trials can thus be reduced through effective management without compromising scientific integrity.
Cardiopulmonary Fitness and Heart Rate Recovery as Predictors of Mortality in a Referral Population
Dhoble, Abhijeet , Lahr, Brian D. , Allison, Thomas G. , Kopecky, Stephen L.

Journal of the American Heart Association | March 25, 2014 | Volume: 3 | Issue: 2 | Pages: No page available

10.1161/jaha.113.000559 | PMID 24663334 Get It

Background Exercise testing provides valuable information in addition to ST ‐segment changes. The present study evaluated the associations among exercise test parameters and all‐cause mortality in a referral population. Methods and Results We examined conventional cardiovascular risk factors and exercise test parameters in 6546 individuals (mean age 49 years, 58% men) with no known cardiovascular disease who were referred to our clinic for exercise stress testing between 1993 and 2003. The association of exercise parameters with mortality was assessed during a follow‐up of 8.1±3.7 years. A total of 285 patients died during the follow‐up period. Adjusting for age and sex, the variables associated with mortality were: smoking, diabetes, functional aerobic capacity ( FAC ), heart rate recovery ( HRR ), chronotropic incompetence, and angina during the exercise. Adjusting for cardiovascular risk factors (diabetes, smoking, body mass index, blood pressure, serum total, HDL , LDL cholesterol, and triglycerides) and other exercise variables in a multivariable model, the only exercise parameters independently associated with mortality were lower FAC (adjusted hazard ratio [ HR ] per 10% decrease in FAC , 1.21; 95% confidence interval [ CI ], 1.13 to 1.29; P <0.001), and abnormal HRR , defined as failure to decrease heart rate by 12 beats at 1 minute recovery (adjusted HR per 1‐beat decrease, 1.05; 95% CI , 1.03 to 1.07; P <0.001). The additive effects of FAC and HRR on mortality were also highly significant when considered as categorical variables. Conclusion In this cohort of patients with no known cardiovascular disease who were referred for exercise electrocardiography, FAC and HRR were independently associated with all‐cause mortality.
Limitations and Strengths of Doppler/Echo Pulmonary Artery Systolic Pressure–Right Heart Catheterization Correlations: A Systematic Literature Review
Finkelhor, Robert S., Lewis, Steven , Pillai, Dilip

Echocardiography | March 25, 2014 | Volume: 32 | Issue: 1 | Pages: 10-18

10.1111/echo.12594 | PMID 24661140 Get It

Aims Because many recent studies have questioned the accuracy of Doppler echocardiography (D) in determining pulmonary artery systolic pressure ( PASP ), we performed a detailed literature analysis attempting add clarity. Methods and Results Studies through 2011 comparing D and right heart catheterization ( RHC ) PASP , with at least 25 studied patients and reporting correlation coefficients (r) were identified. Patient demographics, study characteristics, the percent of patients studied for left or right heart pathologies, and study biases were determined. After adjusting for differing study sizes, each study's r value was used as a single datapoint and dichotomized above or below the entire cohort's mean values. From 32 studies 2604 D‐ RHC parings were reported. Their overall weighted r was 0.68 ± 0.19. Poorer correlations were found for right heart pathologies compared to left heart pathologies (r = 0.58 vs. 0.84, P < 0.001) and for normal PASP patients in a study compared to abnormal PASP patients (r = 0.55 vs. 0.82, P < 0.001). Studies with predominately right heart pathology had a significantly greater D‐ RHC time difference, fewer successful D determinations, a greater percentage of normal PASP s on RHC , and more between‐method differences >10 mmHg. Metaregression analyses indicated that both right heart pathology predominance and a greater percent of normal PASP s on RHC remained associated with poorer correlations. Conclusions D PASP ‐ RHC correlations were high and between‐method differences less in patients with left heart pathology but were poorer for right heart diseases and studies with proportionately more normal PASP s on RHC for which further study is needed.
Teaching Neuro Images : MRI in advanced neuromyelitis optica
Braksick, Sherri A. , Cutsforth‐Gregory, Jeremy K. , Black, David F. , Weinshenker, Brian G. , Pittock, Sean J. , Kantarci, Orhun H. , Pittock, S J , Weinshenker, Brian G

Neurology | March 25, 2014 | Volume: 82 | Issue: 12 | Pages: No page available

10.1212/wnl.0000000000000246 | PMID 24663236 Get It

A phase I trial of MK‐2206 in children with refractory malignancies: A Children's Oncology Group study
Fouladi, Maryam , Perentesis, John P. , Phillips, Christine L. , Leary, Sarah , McGovern, Renee M., Ingle, Ashish M., Ahern, Charlotte H., Ames, Matthew M. , Houghton, Peter J. , Doyle, L. Austin, Weigel, Brenda J. , Blaney, Susan M. , Reid, Joel M. , Leary, Sarah

Pediatric Blood & Cancer | March 25, 2014 | Volume: 61 | Issue: 7 | Pages: 1246-1251

10.1002/pbc.25023 | PMID 24664955 Get It

BackgroundWe report results of a phase I trial designed to estimate the maximum tolerated dose (MTD), describe dose‐limiting toxicities (DLT), and characterize the pharmacokinetic profile of MK‐2206, an AKT inhibitor, in children with refractory or recurrent malignancies.ProcedureMK‐2206 was administered either every other day (Schedule 1), or once a week (Schedule 2) in a 28‐day cycle. Dose escalations in increments of ∼30% were independently made in each part using the rolling‐six design. Serial pharmacokinetic (PK) studies were obtained. Biological studies include analysis of PI3K/PTEN/AKT‐cell signaling pathway in pre and post‐therapy in PBMC and in tumors at diagnosis or recurrence.ResultsFifty patients (26 males, median age 12.6 years [range, 3.1–21.9]) with malignant glioma (16), ependymoma (4), hepatocellular carcinoma (3), gliomatosis cereberi (2), or other tumors (22) were enrolled; 40 were fully evaluable for toxicity (Schedule 1, n = 23; Schedule 2, n = 17). Schedule 1 DLTs included: grade 3 dehydration in 1/6 patients at 28 mg/m2; grade 4 hyperglycemia and neutropenia in 1/6 patients at 45 mg/m2; and grade 3 rash in 3/6 patients at dose level 4 (58 mg/m2). Schedule 2 DLTs included: grade 3 alkaline phosphatase in 1/6 patients at 90 mg/m2; grade 3 rash in 1/6 patients at 120 mg/m2; and grade 3 rash in 2/6 patients at 155 mg/m2.ConclusionsThe recommended pediatric phase 2 dose of MK‐2206 is 45 mg/m2/dose every other day or 120 mg/m2/dose weekly. PK appeared linear over the dose range studied. Pediatr Blood Cancer 2014;61:1246–1251. © 2014 Wiley Periodicals, Inc.
Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug‐Induced Liver Injury Network (DILIN)
Hayashi, Paul H. , Chalasani, Naga , Davern, Timothy J., Talwalkar, Jayant A., Reddy, K. Rajender , Stolz, Andrew , Hoofnagle, Jay H., Barnhart, Huiman Xie , Fontana, Robert J. , Rockey, Don C.

Liver International | March 25, 2014 | Volume: 35 | Issue: 5 | Pages: 1623-1632

10.1111/liv.12540 | PMID 24661785 Get It

AbstractBackground & AimsBecause of the lack of objective tests to diagnose drug‐induced liver injury (DILI), causality assessment is a matter of debate. Expert opinion is often used in research and industry, but its test–retest reliability is unknown. To determine the test–retest reliability of the expert opinion process used by the Drug‐Induced Liver Injury Network (DILIN).MethodsThree DILIN hepatologists adjudicate suspected hepatotoxicity cases to one of five categories representing levels of likelihood of DILI. Adjudication is based on retrospective assessment of gathered case data that include prospective follow‐up information. One hundred randomly selected DILIN cases were re‐assessed using the same processes for initial assessment but by three different reviewers in 92% of cases.ResultsThe median time between assessments was 938 days (range 140–2352). Thirty‐one cases involved >1 agent. Weighted kappa statistics for overall case and individual agent category agreement were 0.60 (95% CI: 0.50–0.71) and 0.60 (0.52–0.68) respectively. Overall case adjudications were within one category of each other 93% of the time, while 5% differed by two categories and 2% differed by three categories. Fourteen per cent crossed the 50% threshold of likelihood owing to competing diagnoses or atypical timing between drug exposure and injury.ConclusionsThe DILIN expert opinion causality assessment method has moderate interobserver reliability but very good agreement within one category. A small but important proportion of cases could not be reliably diagnosed as ≥50% likely to be DILI.
Crista galli mucocele: endoscopic marsupialization via frontoethmoid approach
Cervantes, Sergio S., Cervantes, Sergio Santino, Lal, Devyani

International Forum of Allergy & Rhinology | March 25, 2014 | Volume: 4 | Issue: 7 | Pages: 598-602

10.1002/alr.21321 | PMID 24664572 Get It

BackgroundWe report the first report of an expansile crista galli (CG) mucocele treated surgically by an endoscopic endonasal approach. Only 1 other case of a CG mucocele has been previously reported in the literature. This was treated by a craniotomy approach.Case ReportWe describe the technique employed in endoscopic marsupialization. We also discuss relevant CG anatomy, pneumatization patterns, surgical approaches, and its potential to cause disease, including CG sinusitis and mucocele formation.ConclusionWe present this case to highlight that the growing experience with endoscopic techniques offer us less morbid and more functional alternatives to a variety of lesions that were once tackled by neurosurgical or external approaches. In the contemporary era, the indications for open approaches and craniotomy for frontal sinus and CG lesions is likely limited. We recommend these patients undergo careful evaluation by a surgeon experienced in advanced endoscopic techniques before being advised to undergo open or craniotomy techniques.